scholarly journals Enhancing the cross protective efficacy of live attenuated influenza virus vaccine by supplemented vaccination with M2 ectodomain virus-like particles

Virology ◽  
2019 ◽  
Vol 529 ◽  
pp. 111-121 ◽  
Author(s):  
Young-Tae Lee ◽  
Ki-Hye Kim ◽  
Eun-Ju Ko ◽  
Min-Chul Kim ◽  
Yu-Na Lee ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Protective Efficacy ◽  
Influenza Virus Vaccine ◽  
Virus Like Particles ◽  
The Cross ◽  
Live Attenuated Influenza Virus

An Attenuated Influenza Virus Vaccine: Reactogenicity, Transmissibility, Immunogenicity, and Protective Efficacy

1974 ◽  
Vol 130 (4) ◽  
pp. 380-383 ◽  
Author(s):  
S. F. Lauteria ◽  
G. B. Kantzler ◽  
P. C. High ◽  
J. D. Lee ◽  
R. H. Waldman
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Protective Efficacy ◽  
Influenza Virus Vaccine

scholarly journals Immunogenicity and Protective Efficacy of Seasonal Human Live Attenuated Cold-Adapted Influenza Virus Vaccine in Pigs

2019 ◽  
Vol 10 ◽  
Author(s):  
Barbara Holzer ◽  
Sophie B. Morgan ◽  
Veronica Martini ◽  
Rajni Sharma ◽  
Becky Clark ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Protective Efficacy ◽  
Influenza Virus Vaccine ◽  
Cold Adapted

scholarly journals Development of a Mouse-Adapted Live Attenuated Influenza Virus That PermitsIn VivoAnalysis of Enhancements to the Safety of Live Attenuated Influenza Virus Vaccine

2014 ◽  
Vol 89 (6) ◽  
pp. 3421-3426 ◽  
Author(s):  
Andrew Cox ◽  
Steven F. Baker ◽  
Aitor Nogales ◽  
Luis Martínez-Sobrido ◽  
Stephen Dewhurst
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Safety Analysis ◽  
Influenza Virus Vaccine ◽  
Safety Concerns ◽  
High Doses ◽  
Live Attenuated Influenza Virus

The live attenuated influenza virus vaccine (LAIV) is preferentially recommended for use in persons 2 through 49 years of age but has not been approved for children under 2 or asthmatics due to safety concerns. Therefore, increasing safety is desirable. Here we describe a murine LAIV with reduced pathogenicity that retains lethality at high doses and further demonstrate that we can enhance safetyin vivothrough mutations within NS1. This model may permit preliminary safety analysis of improved LAIVs.

Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs

Vaccine ◽  
2010 ◽  
Vol 28 (43) ◽  
pp. 7098-7108 ◽  
Author(s):  
Aleksandar Masic ◽  
Xinya Lu ◽  
Junwei Li ◽  
George K. Mutwiri ◽  
Lorne A. Babiuk ◽  
...  
Keyword(s):  
Influenza Virus ◽  
Virus Vaccine ◽  
Protective Efficacy ◽  
Swine Influenza Virus ◽  
Swine Influenza ◽  
Influenza Virus Vaccine
Sign in / Sign up

Export Citation Format

Share Document